24 Sep 2009: Nishide K, Nakatani Y, Kiyonari H, Kondo T (2009) Correction: Glioblastoma Formation from Cell Population Depleted of Prominin1-Expressing Cells. PLOS ONE 4(9): 10.1371/annotation/d1e654f7-c02d-458c-8dc7-da7ae96aa594. https://doi.org/10.1371/annotation/d1e654f7-c02d-458c-8dc7-da7ae96aa594 View correction
Prominin1 (Prom1, also known as CD133 in human) has been widely used as a marker for cancer stem cells (CSCs), which self-renew and are tumorigenic, in malignant tumors including glioblastoma multiforme (GBM). However, there is other evidence showing that Prom1-negative cancer cells also form tumors in vivo. Thus it remains controversial whether Prom1 is a bona fide marker for CSCs. To verify if Prom1-expressing cells are essential for tumorigenesis, we established a mouse line, whose Prom1-expressing cells can be eliminated conditionally by a Cre-inducible DTA gene on the Prom1 locus together with a tamoxifen-inducible CreERTM, and generated glioma-initiating cells (GICs-LD) by overexpressing both the SV40 Large T antigen and an oncogenic H-RasL61 in neural stem cells of the mouse line. We show here that the tamoxifen-treated GICs-LD (GICs-DTA) form tumor-spheres in culture and transplantable GBM in vivo. Thus, our studies demonstrate that Prom1-expressing cells are dispensable for gliomagenesis in this mouse model.
Citation: Nishide K, Nakatani Y, Kiyonari H, Kondo T (2009) Glioblastoma Formation from Cell Population Depleted of Prominin1-Expressing Cells. PLoS ONE 4(8): e6869. https://doi.org/10.1371/journal.pone.0006869
Editor: Pedro R. Lowenstein, Cedars-Sinai Medical Center and University of California Los Angeles, United States of America
Received: April 8, 2009; Accepted: August 5, 2009; Published: August 31, 2009
Copyright: © 2009 Nishide et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The Global COE Program “Global Center for Education and Research in Integrative Membrane Biology” from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Recent findings have demonstrated that malignant tumors, including glioblastoma multiforme (GBM), contain cancer stem cells (CSCs), which self-renew and are tumorigenic . Prom1 has been utilized extensively to identify and enrich CSCs from many tumors, including lung cancers, colon cancers, hepatocellular carcinomas, and brain tumors –, using the specific anti-Prom1 antibody that recognizes the glycosylated-form of Prom1 . CSCs as well as tissue-specific stem cells (TSCs) in hypoxic niches are likely dormant, and resistant to anti-cancer drugs and irradiation , . Moreover, it was shown that TSCs are fostered in these niches ,  and can transform into CSCs when they acquire oncogenic mutations . These, together with the finding that hypoxia induces Prom1 expression , suggest that both TSCs and CSCs would be positive for Prom1 in the niche. However, it remains controversial whether Prom1 is a bona fide marker for CSCs as it has been indicated that Prom1-negative glioma cell lines in normoxia become positive for Prom1 in hypoxia, which is one of the characteristics of GBM, and that its expression is reversible upon re-oxygenation . Moreover, there is increasing evidence that Prom1-negative cancer cells from GBMs , colon cancers , and the Daoy medulloblastoma cell line  can form tumors when transplanted in vivo. Thus, these findings raise the possibility that CSCs can alter their Prom1 expression, depending on the culture condition and microenvironment in vivo.
In order to confirm whether Prom1-expressing cells are essential for tumorigenesis, we established mouse glioma-initiating cell (GIC) lines by overexpressing both SV40 Large T antigen (SV40LT) and a constitutive-active form of H-Ras (HRasL61) in neural stem cells (NSCs), whose Prom1-expressing cells can be eliminated genetically. We show here that Prom1 expression is induced in the peripheral cells of tumor-spheres in culture and a portion of glioma in vivo as shown in human GBM –, . We demonstrate that the induced GIC population depleted of Prom1-expressing cells form tumor-spheres in culture and transplantable GBM in vivo. Thus, these results suggest that Prom1-expressing glioma cells are not essential for tumorigenesis in this mouse model.
Results and Discussion
Generation of Prom1 knock-in mice
We replaced the second exon, which contains the first ATG codon on the Prom1 locus, with a floxed-lacZ and DTA (Prom1lacZ,DTA/+) ,  (Figure 1A and 1B) and generated Prom1lacZ,DTA/+ mice that develop normally and are fertile. We also obtained adult Prom1lacZ,DTA/lacZ,DTA mice as reported by another Prom1 knock-in allele  and found that they are also viable and develop normally, indicating that Prom1 is not essential for development and our transgene is not toxic.
(A) Schematic representation of targeted allele. (B) Southern blot analysis of three independent heterozygous lines. (C) Whole mount X-gal staining of E12.5 Prom1lacZ,DTA/+ and WT embryos. Scale, 2 mm. (D) X-gal staining of frozen sections of adult mouse brains. Upper panel shows the whole brain and lower five panels display high magnification images of the squared regions in the upper panel. GM, glomeruli; CC, corpus callosum; LV, lateral ventricle; FH, fimbra of hippocampus; GL, granular layer. Scale, 2 mm (upper panel) and 500 µm (lower panels).
Prom1 expression in embryonic and adult central nervous system
Whole-mount X-gal staining revealed widespread β-galactosidase (β-gal) activity in the developing central nervous system where NSCs exist in abundance (Figure 1C). We detected β-gal activity in the ventricular zone (VZ) of E9.5 embryos to neonatal mice, confirming that Prom1 is expressed in NSCs in the developing brains (Figure S1). Although immunoreactivity of Prom1 antibody was detected only in the VZ in the adult brain (Figure S2) , we found β-gal activity in the cerebellum, midbrain, olfactory bulb, hippocampus, and telencephalon as well (Figure 1D and S2). One possible explanation for the difference observed between our findings and previous findings is that the commercially available anti-Prom1 antibodies recognize limited numbers of Prom1 splicing variants, such as Prom1-s1 , whereas the expression of all of the splice variants may be sensitively detected in our knock-in mice.
Detailed analyses revealed that Prom1 is expressed in the granular layer of the cerebellum, where the interneurons exist, and in the glomeruli of the olfactory bulb, which are composed of axons of olfactory cells and dendrites of olfactory bulb interneurons. (Figure 1D). We also found that 69% of β-gal-positive cells are labeled for S100β in the hippocampus where NSCs exist in the dentate gyrus (Figure 1D and 2A–2C). In VZ of lateral ventricle, 90% and 9.5% of β-gal-positive cells are labeled for S100β (ependymal cells, Figure 2D–2F) and GFAP (SVZ astrocytes, Figure 2Q), respectively. We also found that 7.9% of GFAP-positive SVZ astrocytes are positive for Prom1 (Figure 2Q and 2R), consistent with the past finding that Prom1 is expressed in multipotent SVZ astrocytes in the adult brain . In the corpus callosum, the β-gal activity was detected in S100β-positive astrocytes and GSTπ-positive oligodendrocytes, but not in NeuN-positive neurons, NG2-positive oligodendrocyte precursor cells, or GFAP-positive astrocytes (Figure 2G–2P). We found similar tendencies in other white matter, neocortex and midbrain as shown in Figure 2P. Thus, these data revealed that Prom1 is expressed in various types of differentiated neural cells as well as NSCs in the adult brain.
(A–O) Brain sections of adult Prom1lacZ,DT-A/+ were double-labeled for β-gal, which represents Prom1 expression, and differentiation markers. In hippocampus and ventricular zone, most β-gal positive cells stained for S100β (astrocyte and ependymal cell marker; A–F). In corpus callosum, some β-gal-positive cells labeled for S100β (G–I) and GSTπ (mature oligodendrocytes; J–L) but not for GFAP (another marker for astrocytes; M), NeuN (mature neurons; N), or NG2 (oligodendrocyte precursor cells; O). Scale bars, 10 µm. (P) Quantitative data of differentiation marker-positive cells in β-gal-expressing cells in corpus callosum. Similar trends were observed in the midbrain, neocortex, and other white matter. (Q) Quantitative data of Prom1- and GFAP-positive cells in β-gal-expressing cells in lateral ventricle. (R) In ventricular zone, β-gal-expressing cells (red) were partially labeled for Prom1 (green) and GFAP (white). All nuclei were counterstained with DAPI (blue). Scale bars, 10 µm.
Genetic ablation of Prom1-expressing cells by inducible Cre recombinase in vivo
To eliminate Prom1-expressing cells conditionally, the Prom1lacZ,DTA/+ mice were then crossed with the CAGG-CreERTM transgenic mice that ubiquitously express a tamoxifen-inducible Cre recombinase  and generated Prom1lacZ,DTA/+;CreERTM double heterozygotes. Upon the activation of Cre recombinase, the floxed-lacZ cassette is cut off, leading to the specific elimination of the Prom1-expressing cells by DTA induced upon the activation of Prom1 promoter (Figure 3A). We first examined whether this experimental system works in vivo. As expected, after five consecutive days of intraperitoneal injections of tamoxifen, we induced a number of TUNEL-positive cells in the granular layer of cerebellum, cortex of telencephalon, white matter, and midbrain (Figure 3B, 3C and not shown). In addition, tamoxifen-injected mice lost body weight and showed a walking abnormality caused by functional defects of the cerebellum. They did, however, survive at least 15 days after the final injection (Figure S3A). It will be of interest to further investigate how the elimination of Prom1-expressing cells causes body weight loss in mice. Nonetheless, we could not eliminate Prom1-expressing cells in VZ of the mice and detected migrating neuroblasts in the rostral migratory stream (Figure S3B, arrow) and olfactory bulb, suggesting that neurogenesis was taking place in the mice (Figure S3B). These data indicate that our experimental system works as expected, although the efficiency of DTA induction is dependent on the region or cell types.
(A) Schematic diagram of DTA activation. Tamoxifen-dependent Cre activation deleted the lacZ gene cassette, leading to the induction of DTA expression upon activation of the Prom1 promoter. (B) Intraperitoneal injection of tamoxifen-induced cell death (red) in cerebellum (left panels) and neocortex in telencephalon (right panels) as well as midbrain and white matter (not shown). Arrow heads indicate TUNEL-positive cells in the neocortex. All nuclei were counterstained with DAPI (blue). Scales, 100 µm. (C) The number of TUNEL-positive cells per section were counted in the whole neocortex and in half of one lobule of the cerebellum. The results shown are the mean±s.e.m. of two independent experiments. *P<0.05. Similar results were also observed in the midbrain and white matter (not shown).
Establishment of a mouse model for GBM
To verify whether Prom1-expressing cells are essential for tumorigenesis, we adopted a GIC transplantation method into nude mice rather than tumor induction in the Prom1lacZ,DTA/+;CreERTM mice because the DTA induction efficiency is low in the brain as mentioned above (Figure S3B). To generate a mouse GIC line, we first transfected NSCs from Prom1lacZ,DTA/+;CreERTM line with pBabe-Puro-SV40LT vector, which blocks both p53 and Rb pathways, as high frequencies of mutations in p53 (87%) and Rb (78%) pathways are seen in human GBM , . Then the SV40LT-expressing NSCs were transfected with pCMS-EGFP-H-RasL61 vector, as an increased activation of the Ras signaling pathway is detected in about 90% of human GBM , to establish GIC-Prom1lacZ,DTA/+;CreERTM line (GIC-LD). GICs-LD proliferated faster than their parental NSCs as confirmed by the BrdU incorporation assay (Figure 4A). We also found that when both types of cells were cultured under differentiation conditions, GICs-LD did not show any signs of undergoing differentiation, while their parental cells were labeled for the neuronal marker Tuj1, glial markers O4 and glial fibrillary acidic protein (GFAP), and NSC markers Nestin and Sox2 (not shown) (Figure 4B). Moreover, GICs-LD formed colonies in soft agar whereas their parental cells did not (Figure 4C). Together, these data suggest that GICs-LD are transformed and do not readily differentiate in vitro.
(A) Proliferation of the GICs-LD and their parental cells (NSCs) was determined by BrdU incorporation assay. The results shown are the mean±SD of three cultures. *P<0.05. (B) The proportion of neural lineage marker-positive cells is shown as the mean±SD of two cultures. *P<0.05; **P<0.01. (C) Colony formation ability was examined in soft agar. (D) Brain sections with tumors derived from GICs-LD were stained with hematoxylin and eosin (HE) and for Nestin, GFAP, MBP, and NeuN. Scales, 2 mm (upper left panel), 100 µm (upper right panel), and 200 µm (middle and lower panels).
We then addressed whether GICs-LD form tumors in vivo. We injected 104 cells into brains of nude mice and found that they formed tumors with histological features similar to human GBM, including hypercellularity, pleomorphism, multinuclear giant cells, mitosis, and necrosis  (Figure 4D). In addition, we noticed that the tumors were comprised of Nestin-positive cell populations, rather than a mixture of NSC marker- and differentiation marker-positive cells, GFAP+ astrocytes, myelin basic protein (MBP)+ mature oligodendrocytes, and NeuN+ mature neurons, indicating that the tumor cells maintain characteristics of NSCs and are unlikely to differentiate in vivo (Figure 4D). We also confirmed these results by immunolabeling the tumors for GFP and neural markers (Figure S4).
We found Prom1-expression in a portion of brain tumors, especially in the peripheral region of the tumors (Figure 5), consistent with the previous findings that human GBM contain a small population of Prom1-positive cells –, . To determine whether Prom1-expressing cells reside in the hypoxic region, we immunolabeled different sections with either CD31 for blood vessels or HIF1α for hypoxia in combination with X-GAL staining. Although Prom1-expressing cells were not labeled for HIF1α, they were adjacent to the HIF1α-positive hypoxic regions (Figure S5). In contrast, Prom1-expressing cells were not detected around or near blood vessels (Figure S5). Thus, these data suggest that Prom1 expression may be regulated by a HIF1α-independent hypoxic signal pathway.
Serial brain sections with tumors were stained with HE (upper panels) and X-gal (lower panels). Section #1 and #2 were from two independent regions of the brain. Right panels indicate the high magnification images of the squared region of left panels. X-gal-positive cells were detected in the peripheral region of tumors. Scales, 2 mm (left panels) and 200 µm (right panels).
The GIC population lacking Prom1-expressing cells can form tumor-spheres in vitro
We also found that very few GICs-LD were LacZ-positive when cultured as monolayers, whereas a significant number of these cells expressed LacZ when they formed spheres, suggesting that the Prom1 promoter is activated by cell adhesion and cell-to-cell communication (Figure 6A). To test whether the Prom1-expressing cancer cells are essential for tumorigenesis in this system, we generated GICs-Prom1DTA/+;CreERTM (GICs-DTA) by culturing GICs-LD as a monolayer with 4-hydroxy-tamoxifen, and then established two independent GICs-DTA sublines using limiting dilution methods. The genotype of the sublines was confirmed with genomic PCR analysis (not shown). As shown by Tabu et al , we confirmed that when the Prom1 promoter was activated by a histone deacetylase inhibitor, valproic acid (VPA, 10 mM), over 90% of the cells in GICs-DTA sublines died within 2 days, while over 60% of their parental GICs-LD lines survived under the same conditions (Figure 6A–6C). It was believed that Prom1-positive cells are required for the formation of tumor-spheres in vitro –, , however, we found that GICs-DTA sublines can proliferate and form spheres with no observable defects (Figure 6D), indicating that Prom1-expressing cells are not essential for the maintenance of GIC population in culture.
(A) X-gal staining of monolayer-cultured GICs-LD (Monolayer), their tumor spheres (Sphere), and valproic acid (VPA, 10 mM)-treated cells (lower panels; representative data from three cultures). (B) VPA induced TUNEL-positive cell death in GICs-DTA. All nuclei were counterstained with DAPI (blue). Scales, 100 µm (C) Survival of GICs-LD and GICs-DTA was determined by MTT assay. The results shown are the mean±s.e.m of three cultures. *P<0.001. (D) Sphere formation of GICs-LD and GICs-DTA. Upper schemes indicate the structures of the genome. Scale, 60 µm.
GBM formation from the cell population depleted of Prom1-expressing cells
GICs-DTA sublines were then transplanted into the brains of nude mice. Both sublines produced brain tumors with similar characteristics to their control tumors (Figure 4D and 7A) and human GBM , and led to the death all of the mice like their parental GICs-LD (n = 4 for each cell lines, P = 0.65) (Figure 7B). We could not detect LacZ-positive cells in the tumors, confirming that tumors derived from GICs-DTA sublines do not have any Prom1-expressing cells (not shown). Furthermore, we performed serial transplantation experiments, and found that all of the mice (n = 3) that received secondary transplantation developed brain tumors that were phenocopies of primary ones (data not shown) and died within 30 days (Figure 7C), indicating that GIC-DTA sublines have high capacity for self-renewal. Taken together, these data reveal that Prom1-expressing cancer cells are not essential for tumorigenesis and its maintenance in this GBM model.
(A) Brain sections with tumors derived from GICs-DTA. The GICs invaded into the brain parenchyma. HE staining of the tumors shows necrosis, hypercellularity and hypervascularity, multinuclear giant cells, and mitotic cells; these pathological features are similar to human GBM (upper panels). Immunohistochemical analysis of the tumor for Nestin, GFAP, MBP, and NeuN (middle and lower panels). Scales, 2 mm (upper left panel), 100 µm (upper right panel), and 200 µm (middle and lower panels). (B) Survival curves for mice (n = 4 of each line) injected with 104 GICs-LD (green line) and GICs-DTA (red line). No significance was observed, P = 0.65. (C) Survival curve for mice (n = 3) serially transplanted with 104 GFP-positive primary tumor cells.
Using the Prom1 knock-in allele, we demonstrated that Prom1 is predominantly expressed in differentiated cells as well as NSCs in the adult brain and that mouse GIC populations that eliminate Prom1-expressing cells can proliferate in culture and form transplantable GBM in vivo, suggesting that Prom1 is not a specific marker for NSCs or GICs. However, we cannot exclude the possibility that Prom1-positive glial cells may behave as multipotent NSCs as shown previously ,  and that Prom1-positive GICs may be more malignant than other GICs and are essential for tumorigenesis in other glioma models. It also remains to be evaluated whether human GIC population depleting Prom1-expressing cells can form malignant glioma in vivo. Using the Prom1lacZ,DTA/+ mice, it is important to clarify whether Prom1-expressing cells are essential for the tumorigenesis of other cancers, including breast, intestinal, and prostate cancers. Thus our Prom1lacZ,DTA/+ mice will be a useful tool for the research community to examine the functions of Prom1-expressing cells, which exist throughout the adult body, by crossing them with other transgenic mice that express inducible and tissue-specific Cre recombinase.
Materials and Methods
Mice and Chemicals
Prom1 knock-in mice (Acc. No. CDB0623K: http://www.cdb.riken.jp/arg/mutant%20mice20list.html) were generated using a knock-in method as described . To prevent leaky expression of DTA, a double polyA signal was inserted under the lacZ gene (http://www.cdb.riken.jp/arg/cassette.html). Prom1 knock-in mice that were backcrossed and maintained on a C57BL/6 genetic background, were crossed with ACTB-FLPe mice  to delete the neomycin selection cassette to generate Prom1lacZ,DTA/+ mice. Prom1lacZ,DTA/+ mice were further crossed with CAGG-CreERTM mice to delete the lacZ cassette upon Cre activation, generating Prom1lacZ,DTA/+;CreERTM mice. Genotypes of each mouse were confirmed by Southern blot analysis and PCR. To induce CreER activation, tamoxifen (Sigma), which was dissolved in sun-flower oil (20 mg/ml), was injected intraperitoneally into mice (9 mg/40 g body weight) for 5 consecutive days. The mice were dissected and analyzed 10 days after the final injection. All mouse experiments were performed following the protocols approved by the RIKEN CDB Animal Care and Use Committee.
Chemicals and growth factors were purchased from Sigma and PeproTech, respectively, except where indicated.
Intracranial cell transplantation into the brain of nude mice
Control cells and transformed cells were suspended in 5 µl of culture medium and injected into brains of 5∼8 week-old female nude mice that had been anesthetized with 10% pentobarbital. The stereotactic coordinates of the injection site were 2 mm forward from lambda, 2 mm lateral from the sagittal suture, and 5 mm deep.
For serial transplantation, brain tumors were dissociated enzymatically using the papain dissociation system (Worthington). GFP-positive transformed cells were purified using a JSAN flow cytometer (BayBioscience, Japan), suspended in culture medium, and transplanted into nude mice soon after sorting.
NSCs were prepared from embryonic day 17.5 Prom1lacZ,DTA/+;CreERTM mouse telencephalon and cultured in DMEM/F12 (Gibco, BRL) supplemented with chemicals, bFGF (10 ng/ml), and EGF (10 ng/ml) (NSC medium), as described previously . For the monolayer culture, cells were cultured on poly-D-lysine- (PDL, 15 µg/ml) and fibronectin- (1 µg/ml, Invitrogen) coated dishes in NSC medium or on non-coated dishes in NSCs medium with 5% FCS.
To induce neural differentiation, NSCs were cultured on 8-well chamber slides (Nunc) in DMEM with 1% FCS for one week. Prom1 expression was induced in the cells cultured with 10 mM Valproic acid (VPA) (Calbiochem) for 3 days. BrdU incorporation assay was performed as described previously . To isolate GICs-DTA sublines, GICs-LD were cultured with 4-hydroxy-tamoxifen (100 nM) for 4 days. The single cells were then isolated and cultured in the 96-well dishes to avoid contamination of non-recombinant cells. Deletion of the lacZ gene in GICs-DTA sublines was confirmed by PCR analysis (see below).
Southern blot analysis and genotyping
To determine the genome structure of Prom1 knock-in mice, genomic DNA was digested with XmnI or BamHI. Digoxigenin (DIG)-labeled external or internal probes were generated using PCR DIG Probe Synthesis kit (Roche). Detailed probe sequences will be disclosed on request. Hybridization was conducted using standard protocols. In addition to the external probes (probe A), internal probes (probe B) were used to detect random integrations of the targeting vector on the genome.
Genotyping of the knock-in mice was done by PCR. Genomic DNA was isolated from the mouse tail by standard methods and then used for PCR. The following oligonucleotide DNA primers were synthesized: For Prom1 knock-in allele, prom1-fwd: 5′-GCT TGAGAGATCAGG CCAACAAC-3′, prom1-rvs: 5′-CTAGAGGGAAGTCATTCGGCTG-3′ and lacZas: 5′-CGCGTAAAAATGCGCTCAGG-3′. The primers for CAGG-CreERTM and ACTB-FLPe were as described previously , . Dimethylsulfoxide (DMSO, 5%) was added to the all reaction mixture. Cycle parameters were 20 sec at 94°C, 30 sec at 60°C, and 40 sec at 72°C for 35 cycles.
RT-PCR was carried out as described previously . For gapdh, cycle parameters were 10 sec at 94°C, 20 sec at 58°C, and 40 sec at 72°C for 25 cycles. DNA primers for Prom1 were synthesized: the 5′ primer was 5′-AGGCTACTTTGAACATTATCTGCA-3′ and the 3′ primer was 5′-GGCTTGTCATAACAGGATTGT-3′. Cycle parameters were 10 sec at 94°C, 20 sec at 58°C, and 40 sec at 72°C for 40 cycles.
Immunostaining was carried out as described previously , . The following antibodies were used to detect antigens: rat anti-Prom1 (1∶100; eBioscience), mouse anti-BrdU (1∶1000; Hybridoma Bank), rabbit anti-GFAP (1∶500; DakoCytomation), mouse anti-Nestin (1∶500; BD Pharmingen), mouse anti-beta tubulin isotype III (Tuj1; 1∶200; Sigma), mouse anti-O4 (1∶5; hybridoma supernatant; ATCC), mouse anti-MBP (1∶1000; COVANCE), mouse anti-NeuN (1∶200; Chemicon), rabbit anti-GFP (1∶500; Abcam), rat anti-GFP (1∶500; Nacalai Tesque, Japan), chicken anti-β-gal (1∶500; Abcam), rabbit anti-NG2 (1∶200; Chemicon), rabbit anti-S100β (1∶500; DakoCytomation), mouse anti-GSTπ (1∶100; BD Pharmingen), mouse anti-PSA-NCAM (1∶500; gift from T. Seki, Juntendo University School of Medicine), mouse anti-HIF1α (1∶500; Abcam) and rabbit anti-CD31 (1∶50; Abcam). The antibodies were detected with goat anti-rabbit IgG-A488, goat anti-mouse IgG-A488 (1∶400; Invitrogen), goat anti-mouse IgG-Cy3, donkey anti-rabbit IgG-Cy3, donkey anti-mouse IgG-Cy3, donkey anti-chicken IgY-Cy3, donkey anti-rabbit IgG-Cy5 (1∶200; Jackson ImmunoResearch), and rabbit anti-mouse IgM-Texas-Red (1∶200; Jackson ImmunoResearch). To visualize the nuclei, the cells were counterstained with DAPI (1 µg/ml).
Soft agar assay
We performed a soft agar assay to examine whether the cultured cells could proliferate anchorage-independently. The cells were suspended in 0.3% top agar containing optimum medium and layered onto 0.6% bottom agar made with the same medium. After the top agar solidified, culture medium was added and the cells were cultured for 20 days with medium changes every 3 days.
One thousand cells were cultured in 100 µl of culture medium in each well of the 96-well plates with or without VPA (5 or10 mM) for 2 days. The cells were cultured in the presence of MTT labeling reagent (Roche) for 4 h and then incubated overnight at 37°C with the solubilization solution (10% SDS in 0.01 M HCl). The viable cells were quantified on a microplate reader (Bio-Rad) with the absorption spectrum at 595 nm.
Brain fixation and histopathology
The dissected mouse brains were fixed in 4% paraformaldehyde overnight at 4°C. After fixation, the brains were cryoprotected with 12–18% sucrose in PBS and embedded in Tissue-Tek OCT compound (Miles, Elkhart, IN). Coronal sections (10 µm thick) were prepared from the cerebral cortex and stained with hematoxylin-eosin (HE) using a standard technique.
For X-gal staining, frozen sections (10 µm thick) were fixed by 0.2% glutaraldehyde in PBS or 4% paraformaldehyde in PBS for 5 min, washed several times, and stained X-gal staining solution (2 mg/ml X-gal) for 24 hours.
Immunohistochemical analysis was carried out using the standard ABC method (VECTOR) and fluorescent-dye conjugated secondary antibodies described above. Primary antibodies used in this experiment are described above. For Nestin immunostaining, antigen was retrieved by HistoVT One according to the supplier's instructions (Nacalai Tesque). After the second antibody treatment, samples were incubated in peroxidase substrate solution and then counterstained with hematoxylin. TUNEL assay was carried out as described previously .
Transfection was performed using the Nucleofector system, according to the supplier's instructions (Amaxa). In brief, 2×106 cells were suspended in the Mouse NSC Nucleofector Solution (100 µl) with 10 µg vectors, and were then transfected using the Nucleofector Device. Transfected cells were cultured in their optimized medium and selected with puromycin (0.25 µg/ml) and hygromycin (100 µg/ml). GFP-positive transfected cells were then purified using a flow cytometer (JSAN) as previously described .
Full-length SV40LT cDNA was amplified from pBS-SVT (Japan Health Sciences Foundation, Tokyo, Japan) using PCR and Phusion polymerase (FINNZYME, Espoo, Finland), according to the manufacturer's instructions. Full-length mouse H-Ras was amplified from mouse NSC cDNA using RT-PCR and Phusion polymerase, and H-RasL61 was made by substituting a leucine for the glycine at codon 61 by PCR. Amplified cDNA were cloned into a pDrive vector (QIAGEN). The nucleotide sequences were verified using the BigDye Terminator Kit version 3.1 (Applied Biosystems) and an ABI sequencer model 3130xl (Applied Biosystems). H-RasL61 and SV40LT cDNA were inserted into pCMS-EGFP vector and pBabe-Puro, resulting in pCMS-EGFP-H-RasL61 and pBabe-Puro-SV40LT, respectively. The following oligonucleotide DNA primers were synthesized: For the full-length mouse H-Ras, the 5′ primer was 5′-TGAATTCGCCACCATGACAGAATACAAGCTTGTGGTG-3′ and the 3′ primer was 5′-ACTCGAGTCAGGACAGCACACATTTGCAG-3′. For H-RasL61, the 5′ primer was 5′-ACAGCAGGTCTAGAAGAGTATA-3′ and the 3′ primer was 5′-TATACTCTTCTAGACCTGCTGT-3′. For SV40LT, the 5′ primer was 5′-AGAATTCGCCACCATGGATAAAGTTTTAAACAGAGAG-3′ and the 3′ primer was 5′-AGTCGACTTATGTTTCAGGTTCAGGGGG-3′.
Survival probability was calculated and plotted by Kaplan-Meier methods. The difference was analyzed using the logrank test. Comparison of cell growth, differentiation, and X-GAL induction were performed by the unpaired Student's t-test. Comparison of cell viability and cell death after VPA treatment was performed two-way ANOVA followed by Bonferroni posttests. All statistic analysis was performed using software GraphPad Prism 5.0 (Graphpad Software).
Developmental expression pattern of Prom1. X-gal staining (blue) of frozen sections of E9.5, E12.5, E14.5 and P0 Prom1lacZ,DTA/+ mouse brains. Sections were counterstained with eosin (red) to visualize cytoplasm. Scale, 200 µm.
(4.28 MB TIF)
Prom1 antibody labels Prom1-expressing cells in VZ but not in the other regions. Brain sections of adult Prom1lacZ,DTA/+ mice were immunolabeled for β-gal (red) and Prom1 (green). LV, lateral ventricle; DG, dentate gyrus; GL, granular layer. All nuclei were counterstained with DAPI (blue). Scale, 100 µm.
(2.02 MB TIF)
Tamoxifen injection decreases body weight of Prom1lacZ,DTA/+;CreERTM mice but does not affect VZ cells and their neurogenesis. (A) Relative body weight of mice. Tamoxifen was injected once a day for five consecutive days and body weight were measured every five days up to fifteen days after final injection. PC-TM, tamoxifen-injected Prom1lacZ,DTA/+;CreERTM mouse; PC-oil, oil-injected Prom1lacZ,DTA/+;CreERTM mouse; CreER-TM, tamoxifen-injected CreERTM mouse; Prom1-TM, tamoxifen-injected Prom1lacZ,DTA/+ mouse. (B) Upper panels show X-gal staining of frozen sections of tamoxifen-injected Prom1lacZ,DTA/+;CreERTM mouse brains. Lower four panels indicate PSA-NCAM immunostaining (red) in the ventricular zone and olfactory bulbs in tamoxifen-injected Prom1lacZ,DTA/+;CreERTM mice. Arrows show migrating neuroblasts in rostral migratory stream. All nuclei were counterstained with DAPI (blue). LV, lateral ventricle. Scale, 100 µm.
(2.25 MB TIF)
Brain tumors derived from GICs-LD were labeled for Nestin but not differentiation markers. Brain sections with tumors were immunolabeled for GFP (GICs, green) and either neural stem cell marker (Nestin, red) or differentiation markers, GFAP (astrocytes, red), MBP (oligodendrocytes, red), NeuN (mature neurons, red) and NG2 (oligodendrocytes precursor cells, red). Although most of GFP-positive cells were NG2-negative, very few double-positive cells were detected. Scale, 100 µm.
(5.61 MB TIF)
Prom1-expressing cells were adjacent to hypoxic regions but not to blood vessel. Frozen sections of brain tumors were stained with X-gal activity and then immunoelabeled for GFP (green) and either CD31 (marker for endothelrial cells, red) or HIF1α (marker for hypoxia, red). Arrow heads indicate CD31-positive cells. Scale, 100 µm.
(9.60 MB TIF)
We thank S. Hayashi for critical reading and comments on the manuscript; M. Takeichi and T. Miki for suggestions and comments; H. Enomoto and M. Nagashimada for technical advice on Southern blotting; Y. Sasai and T. Wataya for technical advice on immunohistochemical analysis; T. Seki for anti-PSA-NCAM antibody; T. Hide, T. Takezaki and H. Takanaga for histopathology and mouse genotyping; K. Miwa for the technical advice on flow cytometry; H. Hiraga for critical reading of the manuscript.
Conceived and designed the experiments: KN TK. Performed the experiments: KN YN HK. Analyzed the data: KN. Contributed reagents/materials/analysis tools: YN HK. Wrote the paper: KN TK. Financial support: TK.
- 1. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755–768.
- 2. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, et al. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504–514.
- 3. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111–115.
- 4. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, et al. (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351: 820–824.
- 5. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396–401.
- 6. Mizrak D, Brittan M, Alison MR (2008) CD133: molecule of the moment. J Pathol 214: 3–9.
- 7. Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, et al. (2005) Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 319: 15–26.
- 8. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756–760.
- 9. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, et al. (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67.
- 10. Simon MC, Keith B (2008) The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol 9: 285–296.
- 11. Morrison SJ, Spradling AC (2008) Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell 132: 598–611.
- 12. Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, et al. (2009) Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 457: 603–607.
- 13. Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, et al. (2008) CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE 3: e3655.
- 14. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, et al. (2007) CD133(+) and CD133(−) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67: 4010–4015.
- 15. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, et al. (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111–2120.
- 16. Srivastava VK, Nalbantoglu J (2008) Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype. Cytometry A 73: 940–948.
- 17. Yamaizumi M, Mekada E, Uchida T, Okada Y (1978) One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 15: 245–250.
- 18. Ivanova A, Signore M, Caro N, Greene ND, Copp AJ, et al. (2005) In vivo genetic ablation by Cre-mediated expression of diphtheria toxin fragment A. Genesis 43: 129–135.
- 19. Coskun V, Wu H, Blanchi B, Tsao S, Kim K, et al. (2008) CD133+ neural stem cells in the ependyma of mammalian postnatal forebrain. Proc Natl Acad Sci U S A 105: 1026–1031.
- 20. Corbeil D, Joester A, Fargeas CA, Jaszai J, Garwood J, et al. (2009) Expression of distinct splice variants of the stem cell marker prominin-1 (CD133) in glial cells. Glia 57: 860–874.
- 21. Mirzadeh Z, Merkle FT, Soriano-Navarro M, Garcia-Verdugo JM, Alvarez-Buylla A (2008) Neural stem cells confer unique pinwheel architecture to the ventricular surface in neurogenic regions of the adult brain. Cell Stem Cell 3: 265–278.
- 22. Hayashi S, McMahon AP (2002) Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol 244: 305–318.
- 23. Jeuken J, van den Broecke C, Gijsen S, Boots-Sprenger S, Wesseling P (2007) RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol 114: 121–133.
- 24. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061–1068.
- 25. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807–1812.
- 26. McLendon RE, Provenzale JM, Friedman AH (2006) Glioblastoma. In: Rosenblum MK, McLendon RE, Bigner DD, editors. Russell & Rubinstein's Pathology of Tumors of the Nervous System. London: Hodder Arnold. pp. 103–130.
- 27. Tabu K, Sasai K, Kimura T, Wang L, Aoyanagi E, et al. (2008) Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res 18: 1037–1046.
- 28. Carlen M, Meletis K, Goritz C, Darsalia V, Evergren E, et al. (2009) Forebrain ependymal cells are Notch-dependent and generate neuroblasts and astrocytes after stroke. Nat Neurosci 12: 259–267.
- 29. Murata T, Furushima K, Hirano M, Kiyonari H, Nakamura M, et al. (2004) ang is a novel gene expressed in early neuroectoderm, but its null mutant exhibits no obvious phenotype. Gene Expr Patterns 5: 171–178.
- 30. Rodriguez CI, Buchholz F, Galloway J, Sequerra R, Kasper J, et al. (2000) High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat Genet 25: 139–140.
- 31. Johe KK, Hazel TG, Muller T, Dugich-Djordjevic MM, McKay RD (1996) Single factors direct the differentiation of stem cells from the fetal and adult central nervous system. Genes Dev 10: 3129–3140.
- 32. Kondo T, Raff M (2004) Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells. Genes Dev 18: 2963–2972.
- 33. Takanaga H, Tsuchida-Straeten N, Nishide K, Watanabe A, Aburatani H, et al. (2008) Gli2 Is A Novel Regulator of Sox2 Expression In Telencephalic Neuroepithelial Cells. Stem Cells 27: 165–174.